Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
1 s( K3 t' }( S! r9 X" C8 |, e X) Z7 Z' G, r1 z
) U+ y" z$ B. L$ P& T2 }3 m! jSub-category:
# u3 f% L/ T* k" PMolecular Targets ( M$ u& ^" u$ P0 h8 G: N$ a
& D6 `4 K% Y$ Y- r
( D; f& G' H( O. J' Q5 ?) v% m
Category:
7 a5 F0 q; J R- p5 ^; UTumor Biology
" ^' k" s+ U V" P1 }+ j6 n) ]/ w, _1 O
1 _3 j' }: @' t4 `+ aMeeting: s- H: y0 H* |! i; l, @' D
2011 ASCO Annual Meeting
8 P7 d+ u4 Q2 U8 L1 w! ~' I* G _8 X# s* N) E
3 G% n' T# C1 V! a2 w! O' v
Session Type and Session Title:
( P# E, o% J/ S3 yPoster Discussion Session, Tumor Biology * W+ V4 N! G; h. b" y9 g8 R
9 j9 ^/ E& [& F6 b1 M3 F
+ R6 Q* i; }9 n2 N8 D9 ^6 h4 @: aAbstract No:
) s( M; `# E7 U3 U6 i10517 7 S6 H( t; @' V7 h0 R4 ]% J! @
! Z; y( R: S o
. W& F& K' _$ h& H$ X* X9 L
Citation: s- P4 H, |3 a7 ^' v7 _$ T5 o
J Clin Oncol 29: 2011 (suppl; abstr 10517) ; A& A y$ y7 b. w* e6 y1 I
4 b" K1 b, U" Z$ G8 p. i1 x _
% B5 s' a+ _4 a& Q0 O7 s) k9 r+ D* aAuthor(s):
* f, v# p8 D7 R9 [J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China $ t) ]. p0 R" s; o3 P/ W
1 L8 ^' U2 v( f* j3 n
0 E9 R) N2 E0 \7 _% G3 T, v2 U4 h# I3 K( h
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
* Z2 B B" q% f5 o0 d
. a s$ N2 ?( t7 XAbstract Disclosures& P# X2 `6 u: b" H! y/ A L
' `' Q7 E, V1 D
Abstract:$ g$ l4 W1 c! D7 n
8 V" \: ^& r9 K7 s' P
( u+ Y: g6 k* E$ PBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.! H4 q( q& g% U
8 U$ K' {9 U1 d% R9 s- v, O
E9 W, ]! Y+ _/ s, \
|